Original article
Ambulatory long-term subcutaneous salbutamol infusion in chronic severe asthma

https://doi.org/10.1016/0091-6749(90)90099-PGet rights and content

Abstract

Although most patients with asthma improve with currently available drugs, there appears to be a subset of patients with asthma resistant to intensive treatment, including large doses of systemic corticosteroids. In 10 patients with asthma difficult to treat, a double-blind, placebo-controlled, crossover study was performed to evaluate whether long-term, continuous subcutaneous infusion of large doses of salbutamol, in addition to steroids, could improve pulmonary function, compared with intermittent nebulization of salbutamol. Four weeks of administration of large doses (>14 mg/day) of β2-agonists were well tolerated, elicited a significant decrease of corticosteroid consumption (p < 0.01), and were associated with an improvement in pulmonary function (p < 0.01), compared with run in or the placebo administration period. Mean morning and evening peak expiratory flow rates were similar during all periods, and the variability between morning and evening peak expiratory flow rates was only slightly and nonsignificantly reduced during the period when salbutamol was administered subcutaneously. Both nebulized and subcutaneous salbutamol elicited similar metabolic and muscular side effects, but these untoward reactions never caused any patient to stop the treatment. Local infection at the injection site was observed in two of 10 patients with continuous subcutaneous infusion. Tachyphylaxis to β2-agonist, as measured by the reversibility of FEV1 to inhaled salbutamol 12 hours after the end of each period, did not occur. In conclusion, large doses of β2-agonist administered to patients with severe, chronic, and steroid-dependent asthma were able to improve respiratory function and to decrease corticosteroids requirements.

References (34)

  • R Patterson et al.

    Some indications for methylprednisolone for asthma or other severe allergic disease

    J Allergy Clin Immunol

    (1986)
  • RF Willey et al.

    Comparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic asthma

    Thorax

    (1984)
  • VA Cullum et al.

    Salbutamol: a new, selective β-adrenoceptive receptor stimulant

    Br J Pharmacol

    (1969)
  • S Larsson et al.

    Bronchodilatory effect and side effects by β2-adrenoreceptors stimulants by different modes of administration: tablets, metered aerosol and combination therapy—a study with salbutamol in asthmatics

    Am Rev Respir Dis

    (1969)
  • S Ahrens et al.

    Albuterol: an adrenergic agent for use in the treatment of asthma. Pharmacology, pharrmacokinetics, and clinical use

    Pharmacotherapy

    (1984)
  • J Bousquet et al.

    Adrenergic agonists in asthma

  • RM Cayton et al.

    A comparison of salbutamol given by pressure-packed aerosols or nebulization via IPPB in acute asthma

    Br J Dis Chest

    (1981)
  • Cited by (0)

    From the Clinique des Maladies respiratoires, Centre Hospitalier Universitaire, Montpellier, France.

    ∗∗

    From the Département d'informatique médicale, Centre Hospitalier Universitaire, Montpellier, France.

    ∗∗∗

    Glaxo France, Paris, France.

    View full text